Pacific Biosciences of California (PACB) vs. Viewray (VRAY) Financial Survey

Pacific Biosciences of California (NASDAQ: PACB) and Viewray (NASDAQ:VRAY) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Earnings and Valuation

This table compares Pacific Biosciences of California and Viewray’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pacific Biosciences of California $90.71 million 3.40 -$74.37 million ($0.91) -2.91
Viewray $22.24 million 26.82 -$50.63 million ($1.13) -7.81

Viewray has lower revenue, but higher earnings than Pacific Biosciences of California. Viewray is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

70.5% of Pacific Biosciences of California shares are owned by institutional investors. Comparatively, 50.0% of Viewray shares are owned by institutional investors. 17.8% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 62.8% of Viewray shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Pacific Biosciences of California has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, Viewray has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500.

Profitability

This table compares Pacific Biosciences of California and Viewray’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pacific Biosciences of California -95.97% -97.50% -59.40%
Viewray -193.53% N/A -59.34%

Analyst Recommendations

This is a summary of current ratings for Pacific Biosciences of California and Viewray, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacific Biosciences of California 0 2 1 0 2.33
Viewray 0 0 5 0 3.00

Pacific Biosciences of California currently has a consensus target price of $6.27, suggesting a potential upside of 136.48%. Viewray has a consensus target price of $11.20, suggesting a potential upside of 26.84%. Given Pacific Biosciences of California’s higher probable upside, research analysts clearly believe Pacific Biosciences of California is more favorable than Viewray.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.

About Viewray

ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit